Analytical Data
-
基因名
CD161
- Application
-
别名
KLRB1; KLR-B1; CLEC5B; NKR; NKR-P1; NKR-P1A; NKRP1A; HNKR-P1A; Killer Cell Lectin Like Receptor Subfamily B, Member 1; C-type lectin domain family 5 member B; Natural killer cell surface protein P1A
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q12918
-
表达区间
Gln67~Ser225
-
分子量
24kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD161, also known as the killer cell lectin-like receptor subfamily C member 1 (KLRB1), is a type II transmembrane protein predominantly expressed on natural killer (NK) cells and some T cell subsets. Its role in modulating immune responses makes it an important focus of research, particularly in cancer immunotherapy and infectious diseases. Studies have shown that CD161 acts as an inhibitory receptor, influencing the activation and cytotoxic functions of NK cells, thereby affecting tumor surveillance and pathogen control. The understanding of CD161's signaling pathways and ligand interactions is crucial, as it may open new avenues for therapeutic interventions. Recombinant proteins of CD161 have been developed to study its biological functions, receptor-ligand dynamics, and regulatory mechanisms in immune responses. These recombinant proteins are instrumental for functional assays, structural analysis, and the development of potential CD161-targeted therapies. The increasing interest in modulating CD161 to enhance immune efficacy highlights its potential as a biomarker for immune status and a target for new immunotherapeutic strategies, providing insights into the complex interplay between innate and adaptive immunity.
